Loading page…
Healthcare
Regeneron Pharmaceuticals, Inc. records an AlphaScore of 68/100 in the Healthcare sector, supported by a high safety subscore of 87 and a strong net margin of 31.41%. A key strength of the company is its conservative financial profile, demonstrated by a very low debt-to-equity ratio of 0.06. On the risk side, the company displays sluggish revenue growth of 0.99%, resulting in a lower growth subscore of 49. The stock trades at $746.54 with a trailing price-to-earnings (pe) ratio of 18.46 and a forward PE of 12.11. Return on equity (roe) is 14.41%, with a gross margin of 44.46% and a market capitalization of $76.86 billion, offering a dividend of 0.51. Evidence is limited to the 2026-10-11 snapshot.
Written 11/10/2026, 00:38:56 UTC · Snapshot 11/10/2026